Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
NCT05357612
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-[18F]MH.MZ in both populations.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Neurodegenerative Diseases
- Parkinson Disease
- Parkinson Disease Psychosis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 50 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Vanderbilt University Medical Center
- Last updated on ClinicalTrials.gov
- August 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Tennessee · 1
- Vanderbilt University Medical Center · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.